Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening

被引:15
作者
Gu, Shengqing [1 ,2 ,12 ]
Lheureux, Stephanie [1 ,3 ]
Sayad, Azin [1 ]
Cybulska, Paulina [1 ,4 ]
Hogen, Liat [1 ,4 ]
Vyarvelska, Iryna [1 ,4 ,13 ]
Tu, Dongsheng [5 ]
Parulekar, Wendy R. [5 ]
Nankivell, Matthew [6 ]
Kehoe, Sean [7 ]
Chi, Dennis S. [8 ,9 ]
Levine, Douglas A. [10 ]
Bernardini, Marcus Q. [1 ,4 ]
Rosen, Barry [1 ,4 ,14 ]
Oza, Amit [1 ,3 ]
Brown, Myles [11 ,12 ]
Neel, Benjamin G. [1 ,2 ,10 ]
机构
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada
[3] Univ Toronto, Div Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada
[4] Univ Toronto, Div Gynecol Oncol, Toronto, ON M5G 2M9, Canada
[5] Queens Univ, Canadian Canc Trials Grp, Kingston, ON K7L 3N6, Canada
[6] UCL, Med Res Council, Clin Trials Unit, London WC1V 6LJ, England
[7] Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England
[8] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10065 USA
[9] Weill Cornell Med Coll, Dept Obstet & Gynecol, New York, NY 10021 USA
[10] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, 550 1St Ave, New York, NY 10016 USA
[11] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA
[12] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[13] McMaster Univ, Dept Obstet & Gynecol, Hamilton, ON L8S 4L8, Canada
[14] Beaumont Hosp, Dept Gynecol Oncol, Royal Oak, MI 48073 USA
基金
英国医学研究理事会;
关键词
ovarian cancer; computational; neoadjuvant chemotherapy; primary debunking surgery; PRIMARY DEBULKING SURGERY; NEOADJUVANT CHEMOTHERAPY; CISPLATIN RESISTANCE; SURGICAL CYTOREDUCTION; PERITONEAL CARCINOMA; DRUG-RESISTANCE; TIME-INTERVAL; CELL-LINES; EXPRESSION; EVOLUTION;
D O I
10.1073/pnas.2026663118
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
High-grade serous tubo-ovarian carcinoma (HGSC) is a major cause of cancer-related death. Treatment is not uniform, with some patients undergoing primary debulking surgery followed by chemotherapy (PDS) and others being treated directly with chemotherapy and only having surgery after three to four cycles (NACT). Which strategy is optimal remains controversial. We developed a mathematical frame-work that simulates hierarchical or stochastic models of tumor initi-ation and reproduces the clinical course of HGSC. After estimating parameter values, we infer that most patients harbor chemoresistant HGSC cells at diagnosis and that, if the tumor burden is not too large and complete debulking can be achieved, PDS is superior to NACT due to better depletion of resistant cells. We further predict that earlier diagnosis of primary HGSC, followed by complete debulking, could improve survival, but its benefit in relapsed patients is likely to be limited. These predictions are supported by primary clinical data from multiple cohorts. Our results have clear implications for these key issues in HGSC management.
引用
收藏
页数:12
相关论文
共 77 条
[1]   TUMOR KINETICS, RESPONSE TO CHEMOTHERAPY AND SURVIVAL IN PRIMARY OVARIAN-CANCER [J].
ALAMA, A ;
CHIARA, S ;
MERLO, F ;
RAGNI, N ;
CONTE, PF ;
MEAZZA, R ;
REGGIARDO, G ;
FERRARI, I ;
ROSSO, R .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (04) :449-452
[2]   Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study [J].
Anderson, Garnet L. ;
McIntosh, Martin ;
Wu, Lieling ;
Barnett, Matt ;
Goodman, Gary ;
Thorpe, Jason D. ;
Bergan, Lindsay ;
Thornquist, Mark D. ;
Scholler, Nathalie ;
Kim, Nam ;
O'Briant, Kathy ;
Drescher, Charles ;
Urban, Nicole .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (01) :26-38
[3]   Lead time of rising CA-125 levels less than 35 u/mL predating radiologic confirmation of recurrent ovarian cancer [J].
Bandyopadhyay, J. ;
Ghamande, S. A. ;
Zhang, L. ;
Lan, L. ;
Macfee, M. S. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[4]  
Beale PJ, 2000, BRIT J CANCER, V82, P436
[5]   Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies [J].
Bettegowda, Chetan ;
Sausen, Mark ;
Leary, Rebecca J. ;
Kinde, Isaac ;
Wang, Yuxuan ;
Agrawal, Nishant ;
Bartlett, Bjarne R. ;
Wang, Hao ;
Luber, Brandon ;
Alani, Rhoda M. ;
Antonarakis, Emmanuel S. ;
Azad, Nilofer S. ;
Bardelli, Alberto ;
Brem, Henry ;
Cameron, John L. ;
Lee, Clarence C. ;
Fecher, Leslie A. ;
Gallia, Gary L. ;
Gibbs, Peter ;
Le, Dung ;
Giuntoli, Robert L. ;
Goggins, Michael ;
Hogarty, Michael D. ;
Holdhoff, Matthias ;
Hong, Seung-Mo ;
Jiao, Yuchen ;
Juhl, Hartmut H. ;
Kim, Jenny J. ;
Siravegna, Giulia ;
Laheru, Daniel A. ;
Lauricella, Calogero ;
Lim, Michael ;
Lipson, Evan J. ;
Marie, Suely Kazue Nagahashi ;
Netto, George J. ;
Oliner, Kelly S. ;
Olivi, Alessandro ;
Olsson, Louise ;
Riggins, Gregory J. ;
Sartore-Bianchi, Andrea ;
Schmidt, Kerstin ;
Shih, Ie-Ming ;
Oba-Shinjo, Sueli Mieko ;
Siena, Salvatore ;
Theodorescu, Dan ;
Tie, Jeanne ;
Harkins, Timothy T. ;
Veronese, Silvio ;
Wang, Tian-Li ;
Weingart, Jon D. .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)
[6]   Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma [J].
Bohm, Steffen ;
Montfort, Anne ;
Pearce, Oliver M. T. ;
Topping, Joanne ;
Chakravarty, Probir ;
Everitt, Gemma L. A. ;
Clear, Andrew ;
McDermott, Jackie R. ;
Ennis, Darren ;
Dowe, Thomas ;
Fitzpatrick, Amanda ;
Brockbank, Elly C. ;
Lawrence, Alexandra C. ;
Jeyarajah, Arjun ;
Faruqi, Asma Z. ;
McNeish, Iain A. ;
Singh, Naveena ;
Lockley, Michelle ;
Balkwill, Frances R. .
CLINICAL CANCER RESEARCH, 2016, 22 (12) :3025-3036
[7]   Evolutionary dynamics of cancer in response to targeted combination therapy [J].
Bozic, Ivana ;
Reiter, Johannes G. ;
Allen, Benjamin ;
Antal, Tibor ;
Chatterjee, Krishnendu ;
Shah, Preya ;
Moon, Yo Sup ;
Yaqubie, Amin ;
Kelly, Nicole ;
Le, Dung T. ;
Lipson, Evan J. ;
Chapman, Paul B. ;
Diaz, Luis A., Jr. ;
Vogelstein, Bert ;
Nowak, Martin A. .
ELIFE, 2013, 2
[8]   Dynamics of targeted cancer therapy [J].
Bozic, Ivana ;
Allen, Benjamin ;
Nowak, Martin A. .
TRENDS IN MOLECULAR MEDICINE, 2012, 18 (06) :311-316
[9]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[10]   Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction [J].
Bristow, Robert E. ;
Eisenhauer, Eric L. ;
Santillan, Antonio ;
Chi, Dennis S. .
GYNECOLOGIC ONCOLOGY, 2007, 104 (02) :480-490